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Since the publication of the first mortality results 
from the National Lung Screening Trial (NLST), 
which showed a 20% reduction in lung-cancer 
mortality with low-dose computed tomographic 
(CT) screening,1 the intervention has been adopt-
ed as policy in the United States, and there has 
been considerable discussion of the possibilities 
for its adoption in Europe.2,3 Policy decisions are 
still awaited in many countries, despite the un-
equivocal nature of the original NLST results.1 
This is likely to be partly due to doubts fostered 
by the early publication of inconclusive results of 
a number of smaller trials in Europe.4,5
These doubts should be laid to rest by the re-
sults of the Dutch–Belgian lung-cancer screening 
trial (Nederlands–Leuvens Longkanker Screen-
ings Onderzoek [NELSON]) reported in this is-
sue of the Journal by de Koning et al.6 In this 
trial, arguably the only adequately powered trial 
other than the NLST, 15,792 participants (84% 
male) were randomly assigned to periodic low-
dose CT screening or no screening. At 10 years 
of follow-up, lung-cancer mortality was lower in 
the screening group that in the control group, 
both among men (lower by 24%) and among 
women (lower by 33%). The researchers estimate 
that approximately 60 deaths from lung cancer 
were prevented as a result of four offered rounds 
of screening in 7900 participants.
These results bear out the NLST finding that 
low-dose CT screening reduces lung-cancer mor-
tality. Four further observations may be made. 
First, the intervals between the four screenings 
were 1 year, 2 years, and 2.5 years, as compared 
with strict 1-year intervals in the NLST. This 
suggests that a 2-year interval between screen-
ings would be safe and effective, as has been 
speculated in the past.3 Moreover, Figure 1B in 
the article by de Koning et al. suggests that the 
trajectories of lung-cancer mortality in the two 
trial groups became parallel at 8 years after ran-
domization, approximately 2.5 years after the 
final screening in the trial. The NLST results sug-
gest the same phenomenon occurring approxi-
mately 3.5 years after the final trial screening.7 
These findings imply that the protection afforded 
by a screening lasts between 2.5 and 3.5 years. 
A review of all the trials should further clarify 
this issue. The U.K. Lung Cancer Screening Trial, 
in which a single screening was offered to the 
participants in the screening group, may yield 
information of relevance here.8
Second, the inclusion of a small sample of 
women, seemingly as an afterthought, yielded 
the interesting suggestion of a greater relative 
benefit in women than in men. This too has 
been observed in the NLST and in another trial.9,10 
Further examination of this question is needed 
in the results of the other European trials to 
ascertain whether this is a general phenomenon 
and, more importantly, why it occurs.
Third, the NELSON results suggest overdiag-
nosis of approximately 10% at worst and consid-
erably smaller numbers of overdiagnoses than of 
lives saved. Although there is no room for com-
placency in this regard (there is no “good” way 
to receive a diagnosis of lung cancer), the bal-
ance of overdiagnosis and mortality reduction is 
likely to be acceptable.
Fourth, an important observation relates to 
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the numbers of screened participants undergoing 
further investigation. Results in the past have 
indicated that approximately 20% of participants 
screened then undergo at least one additional 
scan to check for tumor growth or regression. In 
the NELSON trial, this level of additional testing 
was observed only at the first screening, with 
percentages of 1.9 to 6.7% at subsequent 
screenings and an average over all four screen-
ings of less than 10%.
A previous article by the NELSON investiga-
tors provided an insight into the use of nodule 
volume and the doubling time of the nodule 
volume to identify highly suspicious malignant 
nodules.11 Recently, the NELSON investigators 
evaluated both diameter and volume measure-
ment to estimate lung-nodule size as an imaging 
biomarker for nodule management; this provided 
evidence that using mean or maximum axial 
diameter to assess nodule volume led to a sub-
stantial overestimation of nodule volume.12 The 
approach to nodule-volume management described 
by de Koning et al. resulted in a substantial 
number of early-stage cancers identified at the 
time of diagnosis and avoided false positives 
from the overestimation incurred by manage-
ment based on diameter.6
The lung-nodule management system used in 
the NELSON trial has been advocated in the 
European position statement on lung-cancer 
screening.2 This will improve the acceptability of 
the intervention, because the rate of further in-
vestigation has been a major concern in lung-
cancer screening.2
So what are the implications of the NELSON 
results? Most important, there can no longer be 
any doubt as to the efficacy of periodic low-dose 
CT screening in reducing mortality from lung 
cancer. The task for evaluation is now to esti-
mate the cost-effectiveness of this screening. 
The latter, of course, does not have a single value 
and is country-specific. It will depend crucially 
on the interval between screenings and more 
crucially on the population targeted. Selecting 
high-risk persons with the use of validated mod-
els for predicting lung-cancer risk is considered 
essential.2 In an era when most lung cancers in 
developed countries are diagnosed in ex-smokers, 
accurate estimation of individual risk becomes 
more important.
With the NELSON results, the efficacy of low-
dose CT screening for lung cancer is confirmed. 
Our job is no longer to assess whether low-dose 
CT screening for lung cancer works: it does. Our 
job is to identify the target population in which 
it will be acceptable and cost-effective.
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